{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"99"}],"units":"Participants"}],"description":"An SAE is one that results in death, disability/incapacity, or hospitalization or is life threatening, a congenital anomaly or birth defect, cancer, an overdose, or otherwise jeopardizes the participant and may require medical intervention.","groups":[{"description":"Participants who received placebo in Base Study and elected to have open-label 9vHPV vaccination in Extension Study.","id":"OG000","title":"9vHPV Vaccine - Extension Study"}],"paramType":"NUMBER","populationDescription":"All participants who received at least 1 vaccination in Extension Study and had available follow-up data.","reportingStatus":"POSTED","timeFrame":"up to Month 7 - Extension Study","title":"Percentage of Participants Who Experience an SAE- Extension Study","type":"OTHER_PRE_SPECIFIED","unitOfMeasure":"Percentage of Participants"}